Engeletin inhibits Lipopolysaccharide/D-galactosamine-induced liver injury in mice through activating PPAR-γ

Publication date: Available online 19 July 2019Source: Journal of Pharmacological SciencesAuthor(s): Qing Tian, Guijie Wang, Yamin Zhang, Fubo Zhang, Long Yang, Zirong Liu, Zhongyang ShenAbstractLiver injury is a serious clinical syndrome that characterized by inflammatory response. Engeletin is known to have anti-inflammatory activity. However, the effects of engeletin on liver injury remain unclear. We aimed to assess the protective effect of engeletin on Lipopolysaccharide (LPS)/D-galactosamine (D-gal)-induced liver injury in mice. Engeletin was administered intraperitoneally 1 h before and 12 h after LPS/D-gal treatment. The results showed that engeletin treatment on LPS/D-gal-induced liver injury in mice have a significant protective effect, as confirmed by the attenuation of liver histopathologic changes, MPO activity, and serum AST and ALT levels. At the meanwhile, it also showed that engeletin inhibited the levels of IL-β and TNF-α in serum and liver tissues. Besides, engeletin blocked the activation of NF-κB induced by LPS/D-gal and induced the expression of PPAR-γ in a dose-dependently manner. These findings suggested that engeletin may have a protective effect against liver injury.
Source: Journal of Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research